Decreases in the immunoreactivity of next generation PEGylated drugs may be attainable by the use of monofunctionally activated hydroxyPEGs instead of methoxyPEGs in their synthesis.
Speaker:
Merry Sherman, President & Chief Executive Officer, Mountain View Pharmaceuticals

Listen to the audio cast here

[sc_embed_player_template1 fileurl=”http://commondatastorage.googleapis.com/bpidm/Next-Generation-PEGylation-Technology.mp3″]